Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $7.6 million.

  • TransMedics' Capital Expenditures fell 8418.36% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.3 million, marking a year-over-year decrease of 6369.69%. This contributed to the annual value of $129.7 million for FY2024, which is 1455.61% down from last year.
  • As of Q3 2025, TransMedics' Capital Expenditures stood at $7.6 million, which was down 8418.36% from $9.1 million recorded in Q2 2025.
  • Over the past 5 years, TransMedics' Capital Expenditures peaked at $107.7 million during Q3 2023, and registered a low of $20000.0 during Q1 2021.
  • Its 5-year average for Capital Expenditures is $17.9 million, with a median of $4.3 million in 2022.
  • The largest annual percentage gain for TransMedics' Capital Expenditures in the last 5 years was 15875000.0% (2021), contrasted with its biggest fall of 9277.98% (2021).
  • Quarter analysis of 5 years shows TransMedics' Capital Expenditures stood at $3.2 million in 2021, then dropped by 13.0% to $2.8 million in 2022, then surged by 1412.95% to $41.8 million in 2023, then crashed by 67.46% to $13.6 million in 2024, then tumbled by 43.97% to $7.6 million in 2025.
  • Its Capital Expenditures was $7.6 million in Q3 2025, compared to $9.1 million in Q2 2025 and $27.0 million in Q1 2025.